Ce bulletin signale des articles du web anglophone portant sur les divers champs d'intervention de l'Institut national du cancer. La publication se fait sur un rythme quotidien.
"We aren’t trying necessarily to find every neoplasm that exists. A test that does that would have an overdiagnosis problem," he explained. "You want to find the cancer that needs to be found, so that is the upside, maybe, of a sensitivity that is compelling … but not perfect."
More research is needed to improve the test’s ability to catch early cancers and we still need to explore how it might work in a real cancer screening scenario.
The two drugs, trametinib (Mekinist®) and palbociclib (Ibrance®), do not by themselves kill tumor cells. Instead, they trigger a state called senescence.
With liso-cel’s application also securing a speedy review and Zeposia already approved, Bristol Myers now has a good chance to beat all of the deadlines tied to its $9-per-share payout to Celgene shareholders.
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma.
Their study, recently published in the journal Leukemia, shows that these new CAR-T cells could be the answer to resistant leukemia. The new CAR-T cells targeting CD-19, CD-20 and CD-22 are significantly more effective than T-cells that target CD-19 alone.
Gilead’s bid to overturn a jury verdict that ordered it to pay Bristol Myers Squibb about $752 million for CAR-T patents owned by its subsidiary Juno Therapeutics has ended in vain.
“Our cancer patients are uniquely vulnerable to coronavirus. For this reason, we are committing to increased workforce precautions,” said Peter WT Pisters, M.D., president of MD Anderson.
The latest situation, described in the article published in the Annals of Oncology, features tents built in front of each hospital entrance. These tents serve as triage areas.